Grants Review Resource (G2R)
The Office for Research Services is pleased to announce the launch of the Grants Review Resource (G2R) under the leadership of Ravi Iyengar, PhD, Senior Advisor for Research Strategy and Planning and the Dorothy and Lewis H. Rosenstiel Professor of Pharmacology and Systems Therapeutics at the Icahn School of Medicine at Mount Sinai.
This service provides investigators with a confidential preliminary review of their grant proposals and is conducted by fellow investigators who are serving or have recently served on NIH study sections. G2R is a convenient way for investigators to enhance their grant proposals before formally submitting them to a funding agency.
G2R reviews will use the NIH summary statement format to identify areas of the proposal that can be strengthened. The reviewers' identities will be known by the investigator to foster ongoing dialogue, unless the reviewer wishes to remain anonymous.
- Only research grant proposals to federal or state funding agencies such as the NIH, NSF, DOD, and NYSTEM, or select national organizations such as the American Cancer Society and the American Heart Association, will be eligible for G2R review (e.g., R01, R21, U01). Other grant categories may be added in the future.
- Proposals should be sufficiently developed with preliminary data to produce meaningful reviews by G2R.
- Proposals should be submitted to G2R at least four weeks prior to the funding agency's deadline.
- Reviews will be sent to the investigator within five business days after submission.
- Investigators with abbreviated grant application periods may contact G2R to develop a suitable timeline for receiving condensed feedback.
If you would like to take advantage of this unique service, please contact Anthony Grillo, by email or by phone at 212-824-7294.
Office of Research Services (ORS)
Mount Sinai Health System
Center for Advanced Medicine
17 East 102nd Street
4th Floor, West Tower
New York, NY 10029
Conduits is supported by grant #UL1TR001433 funded by the National Center for Advancing Translational Sciences’ Clinical and Translational Science Award (CTSA)